Notice: This company has been marked as potentially delisted and may not be actively trading. NASDAQ:LMNL Liminal BioSciences (LMNL) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock Analysis About Liminal BioSciences Stock (NASDAQ:LMNL) 30 days 90 days 365 days Advanced Chart Ad Chaikin AnalyticsSell NVDA Now?Guess who's selling NVDA next The most successful hedge fund in history quietly sold 500,000 shares. Here's what that means for your money. Billionaire Wall Street investors are quietly offloading millions of shares. What do they know that you don't? It's arguably the most popular stock in the world. Now, one 50-year Wall Street legend says its day in the sun could finally be coming to an end. Last year, he warned of two stocks that went on to crash 60%.Now he's just issued a warning for the most popular stock in the world: Nvidia (NVDA). Get Liminal BioSciences alerts:Sign Up Key Stats Today's Range$8.48▼$8.5050-Day Range$8.38▼$8.5052-Week Range$3.10▼$8.50Volume5,000 shsAverage Volume63,470 shsMarket Capitalization$26.35 millionP/E Ratio29.31Dividend YieldN/APrice TargetN/AConsensus RatingN/A Company OverviewLiminal BioSciences Inc., a development stage biopharmaceutical company, focuses on the development of novel small molecule drug therapeutics for inflammatory, fibrotic, and metabolic diseases in Canada and the United Kingdom. The company is developing LMNL6511, a selective antagonist for the G-protein coupled receptor 84, is expected to commence a Phase 1 clinical trial. It is also developing potential OXER1 antagonists and GPR40 agonists, which are in preclinical stage. The company was formerly known as Prometic Life Sciences Inc. and changed its name to Liminal BioSciences Inc. in October 2019. Liminal BioSciences Inc. was incorporated in 1994 and is headquartered in Laval, Canada.Read More… Sell NVDA Now? (Ad)Guess who's selling NVDA next The most successful hedge fund in history quietly sold 500,000 shares. Here's what that means for your money. Billionaire Wall Street investors are quietly offloading millions of shares. What do they know that you don't? It's arguably the most popular stock in the world. Now, one 50-year Wall Street legend says its day in the sun could finally be coming to an end. Last year, he warned of two stocks that went on to crash 60%.Now he's just issued a warning for the most popular stock in the world: Nvidia (NVDA). Receive LMNL Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Liminal BioSciences and its competitors with MarketBeat's FREE daily newsletter. Email Address LMNL Stock News HeadlinesLIMINAL BIOSCIENCES ANNOUNCES COMPLETION OF THE PLAN OF ARRANGEMENT WITH STRUCTURED ALPHA LPSeptember 26, 2023 | finance.yahoo.comLiminal BioSciences Inc.: LIMINAL BIOSCIENCES RECEIVES FINAL COURT ORDER FOR PLAN OF ARRANGEMENT WITH STRUCTURED ALPHA LPSeptember 19, 2023 | finanznachrichten.de625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetched, but results like this are within reach with the right knowledge and timing in the altcoin market. Plus, you’ll get $10 in real Bitcoin when you stay to the end of the call and take a short quiz.November 2, 2024 | Crypto Swap Profits (Ad)Liminal BioSciences gets final order for the Structured Alpha takeoverSeptember 19, 2023 | msn.comLIMINAL BIOSCIENCES RECEIVES FINAL COURT ORDER FOR PLAN OF ARRANGEMENT WITH STRUCTURED ALPHA LPSeptember 19, 2023 | finance.yahoo.comLIMINAL BIOSCIENCES SHAREHOLDERS APPROVE PLAN OF ARRANGEMENT WITH STRUCTURED ALPHA LPSeptember 15, 2023 | finance.yahoo.comLiminal BioSciences Inc.: LIMINAL BIOSCIENCES FILES AMENDED SCHEDULE 13E-3 AND SUPPLEMENT TO THE MANAGEMENT INFORMATION CIRCULARSeptember 12, 2023 | finanznachrichten.deLIMINAL BIOSCIENCES FILES AMENDED SCHEDULE 13E-3 AND SUPPLEMENT TO THE MANAGEMENT INFORMATION CIRCULARSeptember 12, 2023 | finance.yahoo.comSee More Headlines LMNL Stock Analysis - Frequently Asked Questions How were Liminal BioSciences' earnings last quarter? Liminal BioSciences Inc. (NASDAQ:LMNL) announced its quarterly earnings results on Monday, November, 15th. The company reported $27.40 EPS for the quarter, beating analysts' consensus estimates of ($2.80) by $30.20. The company had revenue of $0.14 million for the quarter, compared to analysts' expectations of $0.02 million. Liminal BioSciences had a net margin of 248.35% and a negative trailing twelve-month return on equity of 88.44%. When did Liminal BioSciences' stock split? Shares of Liminal BioSciences reverse split before market open on Wednesday, February 1st 2023. The 1-10 reverse split was announced on Wednesday, February 1st 2023. The number of shares owned by shareholders was adjusted after the market closes on Wednesday, February 1st 2023. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split. What other stocks do shareholders of Liminal BioSciences own? Based on aggregate information from My MarketBeat watchlists, some other companies that Liminal BioSciences investors own include Corbus Pharmaceuticals (CRBP), Bionano Genomics (BNGO), HubSpot (HUBS), iBio (IBIO), Dynavax Technologies (DVAX), Diamondback Energy (FANG) and NIO (NIO). Company Calendar Last Earnings11/15/2021Today11/02/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:LMNL CUSIPN/A CIK1351172 Webwww.liminalbiosciences.com Phone1-450-781-0115Fax1-450-781-4477Employees251Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)$0.29 Trailing P/E Ratio29.31 Forward P/E RatioN/A P/E GrowthN/ANet Income$380,000.00 Net Margins248.35% Pretax Margin-5,729.40% Return on Equity-88.44% Return on Assets-64.15% Debt Debt-to-Equity Ratio0.02 Current Ratio2.78 Quick Ratio2.78 Sales & Book Value Annual Sales$310,000.00 Price / Sales85.00 Cash FlowN/A Price / Cash FlowN/A Book Value$8.97 per share Price / Book0.95Miscellaneous Outstanding Shares3,100,000Free Float3,036,000Market Cap$26.35 million OptionableNot Optionable Beta1.03 These 7 Stocks Will Be Magnificent in 2024With average gains of 150% since the start of 2023, now is the time to give these stocks a look and pump up your 2024 portfolio.Get This Free Report This page (NASDAQ:LMNL) was last updated on 11/2/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | SponsoredEx WH Advisor Who Predicted Biden Leaving Race Makes Startling New PredictionFormer advisor to the CIA, the Pentagon and the White House Jim Rickards went on multiple TV news programs… ...Paradigm Press | SponsoredHe made 1,303,329 in 12 months after Biden won…Tim Sykes - the world’s most apolitical Millionaire trader - just sat down for an urgent election interview… ...Timothy Sykes | SponsoredSell NVDA Now?Guess who's selling NVDA next The most successful hedge fund in history quietly sold 500,000 shares. Here's...Chaikin Analytics | SponsoredMarket "Famine" ComingMarket Wizard Larry Benedict accurately predicted that all indexes would be negative in 2022... He predicte...Opportunistic Trader | SponsoredHow Will You Survive A Post Election Retirement Heist?The clock is ticking, and your life savings are in an extremely vulnerable position. We are a few days away...American Hartford Gold Group | SponsoredBlackrock’s Sending THIS Crypto Higher on PurposeIt's a groundbreaking opportunity that could be poised for extraordinary gains. The catalyst behind this su...Crypto 101 Media | SponsoredNvidia warning urgentI thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Liminal BioSciences Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Liminal BioSciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.